Vitamin D supplementation in diabetic retinopathy in the era of COVID-19

The outbreak of COVID-19 has generated public health crisis at a global level. The SARS-CoV-2 coronavirus is an enveloped RNA virus. Infection provokes a remarkable range of responses from complete lack of symptoms through to cytokine storm and life-threatening acute respiratory distress syndrome. Mortality from COVID-19 is higher amongst people who are older, male, and obese. All these factors are related with increased prevalence of vitamin D deficiency. Male sex is associated with reduced impact of vitamin D on the immune response.^[1]

Diabetes mellitus is known to be associated with increased risk of infections. Poor glycemic control impairs numerous aspects of the immune response to viral infection and also to the secondary bacterial infection in the lungs. Diabetes does not seem to increase the risk of occurrence of COVID-19, although diabetes is more frequent in patients with severe COVID-19.^[2]

Vitamin D plays a fundamental role in calcium and mineral metabolism. It is needed for the maintenance of normal blood levels of calcium and phosphate that are required for normal mineralization of bone, muscle contraction, nerve conduction, and general cellular function. Vitamin D is also recognized to influence a wide range of fundamental biological functions such as cell differentiation and immunomodulation associating it to variety of clinical disorders such as diabetes, hypertension, autoimmune disorders, and malignancy.^[3] The 25-hydroxyvitamin D (250HD) is the major circulating metabolite and 1,25,-dihydroxy-vitamin D3 (calcitriol) is the biologically active form. Serum 250HD is the most reliable indicator of the vitamin D status of an individual. Serum 250HD levels less than 20 ng/mL is considered as "normal".

Significant evidence supports a link between vitamin D deficiency and COVID-19 severity. Experimentally, vitamin D causes an upsurge in the ratio of angiotensin-converting enzyme 2 (ACE2) to ACE. This increases angiotensin II hydrolysis and reduces subsequent inflammatory cytokine response to pathogens and lung injury.^[1] A significant negative correlation has been observed between mean vitamin D levels and COVID-19 cases per one million population in European countries. However, the correlation of vitamin D with COVID-19 deaths of these countries was not significant.^[4]

Vitamin D plays an important role in normal insulin secretion in response to glucose.^[5-7] Vitamin D is believed to help improve the body's sensitivity to insulin and thus reduce the risk of insulin resistance, which is often a precursor to type 2 diabetes mellitus. Evidences suggest that, through its effects on the immune system, vitamin D may play a role in the pathogenesis of diabetic retinopathy (DR). Inflammatory cytokines, such as TNF- α , TNF- β , IL-6, and plasminogen activator inhibitor-1 are up regulated in type 2 diabetes mellitus. Vitamin D decreases the production of several pro-inflammatory cytokines, such as IL-2, IL-6, IL-8, IL-12, and TNF- α .^[5] Vitamin D also exerts an anti-inflammatory effect by reducing the proliferation of helper T-cells, cytotoxic T-cells, and natural killer cells.^[5] Vitamin D deficiency is also associated with vascular endothelial dysfunction in middle-aged and elderly adults. This dysfunction is linked to increased vascular endothelial cell expression of the pro-inflammatory transcription factor and nuclear factor κB .^[8]

Vitamin D may also contribute to DR via angiogenesis mechanisms. Active metabolite of vitamin D, calcitriol, is a potent inhibitor of retinal neovascularization *in vivo*.^[9] Calcitriol also inhibits retinal endothelial cell capillary morphogenesis *in vitro*.^[9] Moreover, calcitriol downregulates hypoxia-inducible factor-1 (HIF-1) transcriptional activity and HIF-1 target genes, such as vascular endothelial growth factor (VEGF).^[10]

Complications in DR, such as macular edema and neovascularization, are driven by VEGF production.^[11-13] Vitamin D could exert its positive effect via calcitriol mediated VEGF reduction. In my earlier study, deficiency of vitamin D was found to accelerate the severity of retinopathy. Serum vitamin D levels of ≤ 18.6 ng/mL were found to serve as sensitive and specific biomolecular biomarker for proliferative disease, among patients of DR.^[14]

People who are at higher risk of vitamin D deficiency during this global pandemic should consider taking vitamin D supplements to maintain the circulating 25OHD in the optimal levels (75–125 nmol/L). Vitamin D supplementation should be strongly advised for people likely to be deficient.^[1] RDA of 600-800 IU is recommended to maintain adequate levels of vitamin D.^[15] In our country, Indian Council of Medical Research (ICMR) recommends a daily supplement of 400 IU/ day of vitamin D for Indians under situations of minimal exposure to sunlight.^[16]

In India, Vitamin D deficiency is widespread. Clinically diagnosed cases symbolize only the tip of the iceberg. Vitamin D deficiency needs to be taken into consideration with due attention and strong action.^[17]

Diabetes is one of the utmost significant comorbidities related to the severity of COVID-19. There is satisfactory indication of a common pathophysiologic and mechanistic link between diabetes and COVID-19 which is more evident in the presence of vitamin D levels below 10 ng/ml.^[18] In the COVID-19 era, lockdown added to the already existing vitamin D deficiency in the vulnerable group of patients with diabetes mellitus. Levels of 25OHD have been found to be lower in COVID-19 cases who have been hospitalized. Also, such patients had a higher prevalence of deficiency of Vitamin D.^[19] In these unprecedented COVID-19 times, patients of DR should be advised vitamin D supplementation after monitoring serum vitamin D levels.

Sandeep Saxena

Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India E-mail: sandeepsaxena2020@yahoo.com

References

 Rhodes JM, Subramanian E, Laird G, Griffin G, Kenny RA. Vitamin D deficiency and COVID-19 severity – plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. J Intern Med 2021;289:97-115.

- 2. Apicella M, Campopiano MC, Mantuano M, Manzoni L, Copelli A, Prato SD. Covid-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020;8:782-92.
- Holick MF. Vitamin D. The underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2000;9:87-98.
- Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health 2020;13:1373-80.
- Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 2008;10:185-97.
- Gedik A, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon sectretion in man. Diabetologia 1986;29:142-5.
- Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004;79:820-5.
- Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011;57:63-9.
- Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, *et al.* Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 2007;48:2327-34.
- Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1A,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007;6:1433-9.
- Wang J, Xu X, Elliott MH, Zhu M, Le YZ. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010;59:2297-305.
- Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Goto H, *et al*. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-44.
- Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009;148:883-9.

14. Nadri G, Saxena S, Mahdi AA, Kaur A, Ahmad MK, Garg P, *et al.* Serum vitamin D is a biomolecular biomarker for proliferative diabetic retinopathy. Int J Retina Vitreous 2019;5:31-6.

- Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, *et al.* The 2011 report on dietary reference intakes for calcium and Vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
- 16. A Report of the Expert Group of the Indian Council of Medical Research. Jamai-Osmania PO, Hyderabad: National Institute of Nutrition, Indian Council of Medical Research, Nutrient Requirements and Recommended Dietary Allowances for Indians. 2009. [Last accessed on 2014 Jul 12]. Available from: http://www. pfndai.com/Draft_RDA-2010.pdf.
- 17. Aparna P, Muthatha S, Nongkynri B, Gupta SK. Vitamin D deficiency in India. J Fam Med Prim Care 2018;7:324-30.
- Singh SK, Jain R, Singh S. Vitamin D deficiency in patients with diabetes and COVID-19 infection. Diabetes Metab Syndr 2020;14:1033-5.
- Hernandez JL, Nan D, Fernandez-Ayala M, Garcia-Unzueta M, Hernandez-Hernandez MA, Lopez-Hoyos M, *et al.* Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab 2020. doi: 10.1210/clinem/dgaa733.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website:
	www.ijo.in
	DOI: 10.4103/ijo.IJO_3798_20

Cite this article as: Saxena S. Vitamin D supplementation in diabetic retinopathy in the era of COVID-19. Indian J Ophthalmol 2021;69:483-4.



About the author

Prof. Sandeep Saxena

Dr. Sandeep Saxena, MS, FRCSEd, FRCS, FRCOphth, FACS, FAMS, FAICO is Professor and Chief of Retina Service, Department of Ophthalmology, King George's Medical University, Lucknow, India. He has been Fellow, Barnes Retina Institute and Eye Institute, St. Louis, USA, Fellow, New York-Presbyterian Hospital, New York, USA and DAAD Fellow, Augenklinik, Bonn, Germany. He has been a Visiting Fellow to Harvard Medical School, Boston, USA, Oxford Eye Hospital, Oxford, UK and a Visiting Professor to several universities across the globe. He has over 150 publications, 25 published textbooks and has designed an instrument 'Ocular Saxena Retinal Grid-520 and 428. He has published OCT-based classification systems for diabetic retinopathy and clinical classification for Eales' disease.